We canât show the full text here under this license. Use the link below to read it at the source.
Reviewing the Potential of Psychedelics for the Treatment of PTSD
The possible use of psychedelics to treat PTSD
AI simplified
Abstract
Two psychedelics have received breakthrough designations for psychiatric use from the US Food and Drug Administration.
- Psychotherapy is established as a first-line treatment for posttraumatic stress disorder (), but many patients remain symptomatic.
- Current medications for PTSD are limited, and new drug development has not progressed significantly.
- Psychedelic drugs are being explored as potential treatments for PTSD, with several currently under investigation.
- Compounds such as 3,4-methylenedioxymethamphetamine, , classical psychedelics, and cannabinoids may offer distinct therapeutic benefits.
- The review outlines how these compounds can be used to target PTSD symptoms rapidly or as adjuncts to psychotherapy.
- Future research questions are proposed to further investigate the role of these compounds in treating PTSD.
AI simplified
Key numbers
83%
Remission Rate
Patients in the group vs. placebo group.
7 days
Single Infusion Effect Duration
Duration of significant symptom reduction after 0.5 mg/kg infusion.
5 times
Improvement Duration with Mindfulness Therapy
Duration of CAPS-IV symptom reduction with combined treatment.